Aurelia Smith, MD
Neurology · Burlington, VTNPI 1316277098
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $709 of the $1,034 with a category attached, or 68.5%. 16 manufacturers reported payments, led by AstraZeneca at 45.5% of the total. Reporting peaked in 2022 at $648 and has fallen 94.4% since, to $36 in 2025.
Across 43 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$471
- Biogen$100
- Sanofi-aventis U.S. LLC$66
- Lilly USA, LLC$55
- AbbVie$53
- Amgen$49
- plus $240 from 10 others
What the payments were for
- Food & beverage$70969%
- Education$32631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $471 |
| Biogen | 6 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $66 |
| Lilly USA, LLC | 3 | $55 |
| AbbVie | 3 | $53 |
| Amgen(2 entities) | 3 | $49 |
| Bristol Myers Squibb | 3 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$100
How this compares
$1,034 in reported general payments places this provider in the 65th percentile of 41 neurology providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dimethyl Fumarate | 29 | $49,223 |
| AptiomEslicarbazepine Acetate | 15 | $37,749 |
| Dalfampridine ErDalfampridine | 11 | $8,712 |
| Levetiracetam | 40 | $1,682 |
| Gabapentin | 52 | $1,548 |
| Divalproex Sodium | 11 | $1,187 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 29 | $1,007 |
| Primidone | 36 | $952 |
| Propranolol Hcl ErPropranolol Hcl | 15 | $722 |
| Baclofen | 37 | $664 |
| Memantine Hcl | 18 | $462 |
| Phenytoin Sodium Extended | 16 | $454 |
| Tizanidine Hcl | 11 | $377 |
| Duloxetine Hcl | 21 | $353 |
| Lamotrigine | 11 | $269 |
Paid to pharmacies, not to this prescriber.
Other neurology in Burlington
- Michael HehirBurlington$145K
- Andrew SolomonBurlington$142K
- Peter CalabresiBurlington$98K
- Robert ShapiroBurlington$90K
- Rup TandanBurlington$53K
- Chantal Roy-HewitsonBurlington$51K
- Noah KolbBurlington$22K
- James BoydBurlington$20K
- Waqar WaheedBurlington$13K
- Robert HamillBurlington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.